Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free CAPR Stock Alerts

Capricor Therapeutics (CAPR) Financials

Capricor Therapeutics logo
$6.65 +2.44 (+57.96%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$6.51 -0.14 (-2.15%)
As of 08/14/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Capricor Therapeutics

Annual Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Consolidated Net Income / (Loss)		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Net Income / (Loss) Continuing Operations		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Total Pre-Tax Income 		-13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Total Operating Income		 -13 -17 -13 -15 -7.73 -14 -21 -30 -24 -43 -108
Total Gross Profit		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Total Revenue		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Operating Revenue		 5.52 4.00 2.67 1.67 1.01 0.31 0.24 2.55 25 22 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 18 21 16 17 8.74 14 21 32 49 65 108
Selling, General & Admin Expense		 4.37 4.93 4.76 4.93 3.60 5.54 7.61 10 13 15 24
Research & Development Expense		 14 16 11 12 5.14 8.46 14 22 36 50 84
Other Special Charges / (Income)		 - - - 0.00 - - 0.01 0.03 0.01 0.11 0.16
Total Other Income / (Expense), net		 -0.25 -1.83 15 0.14 0.09 0.03 0.92 0.71 1.79 2.21 3.26
Interest Expense		 0.25 0.34 0.40 - - 0.00 0.00 - - 0.00 3.05
Interest & Investment Income		 0.00 0.01 0.04 0.14 0.09 0.03 0.06 0.52 1.73 2.20 6.26
Other Income / (Expense), net		 0.00 -1.50 16 - -0.00 0.00 0.87 0.19 0.07 0.01 0.05
Income Tax Expense		 - - - - - - - - - 0.00 0.00
Basic Earnings per Share		 ($0.81) ($1.01) $0.10 ($5.17) ($2.06) - ($0.87) ($1.18) ($0.83) ($1.15) ($2.26)
Weighted Average Basic Shares Outstanding		 15.90M 18.55M 23.19M 2.94M 3.71M 15.57M 23.09M 24.55M 26.78M 35.22M 46.48M
Diluted Earnings per Share		 ($0.81) ($1.01) $0.09 ($5.17) ($2.06) - ($0.87) ($1.18) ($0.83) ($1.15) ($2.26)
Weighted Average Diluted Shares Outstanding		 15.90M 18.55M 26.79M 2.94M 3.71M 15.57M 23.09M 24.55M 26.78M 35.22M 46.48M
Weighted Average Basic & Diluted Shares Outstanding		 15.90M 18.55M 23.19M 2.94M 3.71M 15.57M 24.30M 25.26M 31.40M 45.68M 57.51M

Quarterly Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.70 -9.79 -11 -13 -7.06 -24 -26 -25 -30 -34 -41
Consolidated Net Income / (Loss)		 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30 -34 -41
Net Income / (Loss) Continuing Operations		 -0.77 -9.79 -11 -13 -7.00 -24 -26 -25 -30 -34 -41
Total Pre-Tax Income 		-0.77 -9.79 -11 -13 -7.00 -24 -26 -25 -30 -34 -41
Total Operating Income		 -1.28 -10 -12 -13 -7.70 -25 -28 -26 -29 -37 -43
Total Gross Profit		 12 4.91 3.97 2.26 11 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 12 4.91 3.97 2.26 11 0.00 0.00 0.00 - 0.00 0.00
Operating Revenue		 12 4.91 3.97 2.26 11 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 13 15 16 15 19 25 28 26 29 37 43
Selling, General & Admin Expense		 3.43 4.07 3.06 3.46 4.27 6.07 5.67 5.92 6.02 9.40 14
Research & Development Expense		 9.94 11 13 12 15 19 22 20 23 27 29
Total Other Income / (Expense), net		 0.52 0.47 0.59 0.45 0.58 0.74 1.81 1.71 -1.01 2.83 2.21
Interest & Investment Income		 0.45 0.47 0.59 0.45 0.69 0.73 1.79 1.71 2.02 2.90 2.21
Other Income / (Expense), net		 - 0.00 0.00 0.00 - 0.01 0.01 0.01 0.01 0.01 0.00
Income Tax Expense		 - - - - - 0.00 0.00 - - 0.00 0.00
Basic Earnings per Share		 $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62) ($0.59) ($0.70)
Weighted Average Basic Shares Outstanding		 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M 57.43M 57.93M
Diluted Earnings per Share		 $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62) ($0.59) ($0.70)
Weighted Average Diluted Shares Outstanding		 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M 57.43M 57.93M
Weighted Average Basic & Diluted Shares Outstanding		 31.40M 31.81M 32.54M 45.47M 45.68M 45.71M 45.72M 45.72M 57.51M 57.91M 58.14M

Annual Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -2.47 -1.02 2.33 -2.34 -0.65 29 2.22 -25 5.09 -3.41 277
Net Cash From Operating Activities		 -11 -14 -14 -14 -6.82 -10 -17 4.92 -26 -40 -70
Net Cash From Continuing Operating Activities		 -11 -14 -14 -14 -6.82 -10 -17 4.92 -26 -40 -70
Net Income / (Loss) Continuing Operations		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Consolidated Net Income / (Loss)		 -13 -19 2.43 -15 -7.64 -14 -20 -29 -22 -40 -105
Depreciation Expense		 0.11 0.13 0.14 0.16 0.17 0.14 0.25 0.53 1.07 1.43 1.89
Non-Cash Adjustments To Reconcile Net Income		 1.67 3.46 -15 1.57 0.97 1.60 2.31 4.50 -2.45 9.83 31
Changes in Operating Assets and Liabilities, net		 0.26 0.77 -2.27 -0.40 -0.33 1.87 0.66 29 -1.93 -11 1.89
Net Cash From Investing Activities		 -8.14 -5.19 4.98 4.67 -3.00 5.44 -1.20 -35 5.11 -116 97
Net Cash From Continuing Investing Activities		 -8.14 -5.19 4.98 4.67 -3.00 5.44 -1.20 -35 5.11 -116 97
Purchase of Property, Plant & Equipment		 -0.15 -0.19 -0.03 -0.32 0.00 -0.55 -1.20 -2.00 -1.31 -1.17 -2.90
Purchase of Investments		 -18 -18 -19 -18 -6.00 -6.13 0.00 -114 -97 -208 -151
Sale and/or Maturity of Investments		 10 13 24 23 3.00 12 0.00 83 105 94 261
Other Investing Activities, net		 - - - - - - 0.00 -1.36 -0.74 -0.37 -8.82
Net Cash From Financing Activities		 16 19 12 6.85 9.18 33 20 4.87 26 153 249
Net Cash From Continuing Financing Activities		 16 19 12 6.85 9.18 33 20 4.87 26 153 249
Issuance of Common Equity		 16 14 11 6.71 9.17 27 20 4.80 26 152 237
Other Financing Activities, net		 - - 0.01 0.14 0.00 5.72 0.05 0.07 0.06 0.45 12
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 5.71 -8.48 4.47 58 -57 18 -5.55 -3.73 268 -182 -84
Net Cash From Operating Activities		 -12 -1.27 -12 -12 -15 -6.43 -20 -20 -24 -29 -31
Net Cash From Continuing Operating Activities		 -12 -1.27 -12 -12 -15 -6.43 -20 -20 -24 -29 -31
Net Income / (Loss) Continuing Operations		 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30 -34 -41
Consolidated Net Income / (Loss)		 -0.76 -9.79 -11 -13 -7.12 -24 -26 -25 -30 -34 -41
Depreciation Expense		 0.31 0.33 0.36 0.36 0.38 0.41 0.49 0.49 0.50 0.53 0.56
Non-Cash Adjustments To Reconcile Net Income		 -7.97 13 2.14 2.00 -7.57 16 3.63 4.38 7.26 6.25 6.66
Changes in Operating Assets and Liabilities, net		 -3.17 -5.06 -3.79 -1.45 -0.49 1.37 1.67 0.01 -1.16 -2.10 2.03
Net Cash From Investing Activities		 -5.86 -9.50 15 2.00 -123 24 15 16 43 -155 -49
Net Cash From Continuing Investing Activities		 -5.86 -9.50 15 2.00 -123 24 15 16 43 -155 -49
Purchase of Property, Plant & Equipment		 -0.56 -0.61 -0.06 -0.01 -0.49 -0.90 -0.29 -0.06 -1.66 -5.12 -4.06
Purchase of Investments		 -25 -33 -16 -20 -139 -18 -60 -58 -15 -175 -76
Sale and/or Maturity of Investments		 20 24 31 22 17 43 76 78 63 31 33
Other Investing Activities, net		 -0.17 -0.06 -0.02 -0.05 -0.25 -0.24 -1.16 -3.95 -3.46 -5.63 -1.84
Net Cash From Financing Activities		 23 2.29 2.07 67 81 0.05 0.02 0.01 249 1.47 -4.24
Net Cash From Continuing Financing Activities		 23 2.29 2.07 67 81 0.05 0.02 0.01 249 1.47 -4.24
Other Financing Activities, net		 0.00 0.00 0.08 0.12 0.25 0.05 0.02 0.01 12 1.47 -4.24

Annual Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 16 19 16 9.25 11 35 41 50 59 170 356
Total Current Assets		 14 18 16 8.47 11 34 36 43 51 163 323
Cash & Equivalents		 5.57 3.20 6.14 4.26 3.90 33 35 9.60 15 11 288
Short-Term Investments		 8.00 13 7.98 3.00 5.99 - 0.00 32 25 140 30
Prepaid Expenses		 0.21 0.34 0.50 0.72 0.57 1.01 1.16 0.92 1.00 1.50 4.81
Plant, Property, & Equipment, net		 0.32 0.44 0.37 0.57 0.44 0.85 1.80 4.59 5.56 5.56 18
Total Noncurrent Assets		 1.76 0.20 0.19 0.20 0.13 0.09 3.10 2.35 2.32 1.53 15
Other Noncurrent Operating Assets		 0.07 0.06 0.10 0.15 0.12 0.09 3.10 2.35 2.32 1.53 15
Total Liabilities & Shareholders' Equity		 16 19 16 9.25 11 35 41 50 59 170 356
Total Liabilities		 17 23 5.05 4.63 4.27 6.42 9.96 38 36 25 50
Total Current Liabilities		 6.53 4.90 1.67 1.26 0.90 2.97 4.13 24 31 21 36
Accounts Payable		 2.88 3.53 1.67 1.26 0.90 2.72 3.72 4.83 6.25 3.28 1.65
Accrued Expenses		 - - - - - - - - - 4.91 16
Current Deferred Revenue		 3.65 1.37 - - - - 0.00 18 24 12 12
Other Current Liabilities		 - - - - - - 0.42 0.77 0.75 0.83 6.62
Total Noncurrent Liabilities		 11 18 3.38 3.38 3.38 3.45 5.83 15 4.86 3.99 14
Other Noncurrent Operating Liabilities		 0.51 3.95 3.38 3.38 3.38 3.38 2.45 1.88 4.86 3.99 14
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Total Preferred & Common Equity		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -1.03 -4.00 11 4.62 6.84 28 31 12 23 145 306
Common Stock		 34 50 63 71 81 116 139 149 182 344 610
Retained Earnings		 -35 -54 -52 -67 -74 -88 -108 -137 -159 -200 -305
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.00 0.01 0.01 -0.00 - 0.00 0.11 0.24 1.03 0.28

Quarterly Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 54 46 37 49 38 93 154 134 126 326 369
Total Current Assets		 47 39 30 41 31 86 146 124 101 283 242
Cash & Equivalents		 11 9.84 8.98 6.21 11 68 29 23 20 105 21
Short-Term Investments		 35 28 20 34 19 17 116 100 79 173 217
Prepaid Expenses		 0.88 0.58 0.46 1.13 0.84 0.39 1.41 1.27 2.33 4.48 4.19
Plant, Property, & Equipment, net		 4.81 4.79 5.14 5.89 5.62 5.32 6.13 8.00 11 29 36
Total Noncurrent Assets		 2.19 2.03 2.49 1.85 1.99 1.81 1.38 1.45 14 15 89
Other Noncurrent Operating Assets		 2.19 2.03 2.49 1.85 1.99 1.81 1.38 1.45 14 15 89
Total Liabilities & Shareholders' Equity		 54 46 37 49 38 93 154 134 126 326 369
Total Liabilities		 48 43 39 31 27 25 26 29 43 48 123
Total Current Liabilities		 37 35 33 26 22 20 22 28 28 34 33
Accounts Payable		 5.41 5.13 6.77 6.25 6.17 6.53 5.25 4.81 2.72 3.93 3.08
Accrued Expenses		 - - - - - - 4.24 7.36 9.93 11 16
Current Deferred Revenue		 31 29 25 19 15 13 12 12 12 12 12
Other Current Liabilities		 0.69 0.71 0.75 0.77 0.79 0.81 0.84 4.23 3.50 7.18 1.49
Total Noncurrent Liabilities		 11 8.13 6.01 4.63 4.42 4.21 3.78 0.19 14 14 90
Other Noncurrent Operating Liabilities		 1.70 1.52 1.68 1.25 1.04 0.83 3.78 0.19 14 14 90
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.21 2.73 -1.79 18 12 68 128 105 84 279 246
Total Preferred & Common Equity		 6.21 2.73 -1.79 18 12 68 128 105 84 279 246
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.21 2.73 -1.79 18 12 68 128 105 84 279 246
Common Stock		 151 155 157 187 192 261 350 354 358 618 626
Retained Earnings		 -145 -152 -159 -169 -180 -193 -224 -250 -275 -339 -380
Accumulated Other Comprehensive Income / (Loss)		 0.09 0.18 0.11 0.31 0.15 0.10 1.81 1.39 0.84 -0.25 -0.16

Annual Metrics And Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 16,254,985.00 21,399,019.00 25,710,074.00 31,067,359.00 4,246,225.00 20,447,504.00 24,149,155.00 - - - 45,718,475.00
DEI Adjusted Shares Outstanding		 1,625,498.00 2,139,902.00 2,571,007.00 3,106,736.00 4,246,225.00 20,447,504.00 24,149,155.00 - - - 45,718,475.00
DEI Earnings Per Adjusted Shares Outstanding		 -7.91 -8.79 0.95 -4.89 -1.80 -0.67 -0.83 - - - -2.30
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -8.83 -12 -13 -11 -5.41 -9.58 -15 -21 -17 -30 -76
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -74.57% -20.48% -24.76%
Earnings before Interest and Taxes (EBIT)		 -13 -18 2.79 -15 -7.74 -14 -20 -30 -24 -43 -108
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -18 2.94 -15 -7.56 -14 -20 -29 -23 -41 -106
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -9.69 -17 -11 -5.29 -8.48 -19 5.60 -26 -41 -69
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -5.44 -7.64 -3.64 -2.93 -3.05 -4.15 -0.14 -27 -17 -6.05 -12
Increase / (Decrease) in Invested Capital		 2.66 -2.20 4.00 0.71 -0.12 -1.10 4.01 -26 9.64 11 -6.28
Book Value per Share		 ($0.06) ($0.19) $0.44 $0.15 $1.61 $1.38 $1.30 $0.47 $0.73 $3.20 $6.69
Tangible Book Value per Share		 ($0.17) ($0.19) $0.43 $0.15 $1.61 $1.38 $1.30 $0.47 $0.73 $3.20 $6.69
Total Capital		 8.12 9.90 11 4.62 6.84 29 35 15 23 145 306
Total Debt		 9.16 14 0.00 0.00 0.00 0.32 3.38 3.38 0.00 0.00 0.00
Total Long-Term Debt		 9.16 14 0.00 0.00 0.00 0.07 3.38 3.38 0.00 0.00 0.00
Net Debt		 -4.41 -3.64 -15 -7.54 -9.89 -32 -32 -38 -39 -152 -318
Capital Expenditures (CapEx)		 0.15 0.19 0.03 0.32 0.00 0.55 1.20 2.00 1.31 1.17 2.90
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.11 -4.33 -0.82 -0.33 -0.24 -1.71 -2.58 -22 -20 -9.16 -31
Debt-free Net Working Capital (DFNWC)		 7.46 13 14 7.22 9.65 31 32 19 20 142 287
Net Working Capital (NWC)		 7.46 13 14 7.22 9.65 31 32 19 20 142 287
Net Nonoperating Expense (NNE)		 4.03 6.92 -15 4.46 2.23 4.07 5.37 8.23 5.43 11 29
Net Nonoperating Obligations (NNO)		 -4.41 -3.64 -15 -7.54 -9.89 -32 -32 -38 -39 -152 -318
Total Depreciation and Amortization (D&A)		 0.11 0.13 0.14 0.16 0.17 0.14 0.25 0.53 1.07 1.43 1.89
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($8.10) ($10.10) $1.00 ($5.20) ($2.06) ($0.88) $0.00 ($1.18) ($0.83) ($1.15) ($2.26)
Adjusted Weighted Average Basic Shares Outstanding		 1.80M 2.14M 2.32M 3.37M 8.91M 22.80M 23.09M 24.55M 26.78M 35.22M 46.48M
Adjusted Diluted Earnings per Share		 ($8.10) ($10.10) $0.90 ($5.20) ($2.06) ($0.88) $0.00 ($1.18) ($0.83) ($1.15) ($2.26)
Adjusted Weighted Average Diluted Shares Outstanding		 1.80M 2.14M 2.68M 2.94M 8.91M 22.80M 23.09M 24.55M 26.78M 35.22M 46.48M
Adjusted Basic & Diluted Earnings per Share		 ($8.10) ($10.10) $0.00 ($5.20) ($2.06) ($0.88) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.59M 1.86M 2.77M 2.94M 3.71M 15.57M 24.30M 25.26M 31.40M 45.68M 57.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.83 -12 -9.00 -11 -5.41 -9.58 -15 -21 -17 -30 -76
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - 45,676,202.00 45,707,819.00 45,716,975.00 45,718,475.00 57,510,635.00 57,911,893.00
DEI Adjusted Shares Outstanding		 - - - - - 45,676,202.00 45,707,819.00 45,716,975.00 45,718,475.00 57,510,635.00 57,911,893.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - -0.53 -0.57 -0.54 -0.66 -0.59 -0.70
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,159.30% 64.29% 1.38% -63.44% -7.92% -100.00% -100.00% -100.00% - 0.00% 0.00%
EBITDA Growth		 87.64% -24.89% -49.94% -91.99% -652.00% -147.27% -142.28% -103.84% - -47.49% -55.72%
EBIT Growth		 84.12% -25.43% -49.62% -89.52% -500.79% -143.24% -139.01% -101.98% - -47.23% -55.02%
NOPAT Growth		 84.12% -25.43% -49.62% -89.52% -500.79% -143.36% -139.14% -102.03% - -47.19% -54.94%
Net Income Growth		 90.13% -26.08% -49.32% -96.49% -833.83% -149.04% -135.56% -95.68% - -39.15% -57.21%
EPS Growth		 106.45% 0.00% -20.69% -52.00% -650.00% -70.97% -62.86% -42.11% - -11.32% -22.81%
Operating Cash Flow Growth		 -67.98% -130.13% -30.48% -32.38% -27.62% -407.20% -63.75% -69.11% - -354.73% -56.47%
Free Cash Flow Firm Growth		 -150.81% -11,883.28% -816.52% -298.59% -53.93% 23.84% 36.58% 24.57% - -129.08% -237.35%
Invested Capital Growth		 36.34% 48.66% 54.36% 50.29% 64.15% 6.89% -22.22% -9.80% - 100.54% 137.24%
Revenue Q/Q Growth		 95.42% -59.41% -19.06% -43.05% 392.14% -100.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Q/Q Growth		 85.22% -920.30% -13.08% -12.59% 42.11% -235.49% -10.80% 5.27% - -26.49% -16.98%
EBIT Q/Q Growth		 81.33% -701.21% -12.91% -12.24% 40.83% -224.38% -10.95% 5.15% - -26.15% -16.81%
NOPAT Q/Q Growth		 81.33% -701.21% -12.91% -12.24% 40.83% -224.54% -10.95% 5.18% - -26.12% -16.79%
Net Income Q/Q Growth		 88.07% -1,185.16% -12.31% -14.15% 43.32% -242.74% -6.23% 5.17% - -12.50% -20.01%
EPS Q/Q Growth		 108.00% -1,650.00% -12.90% -8.57% 71.05% -381.82% -7.55% 5.26% - 4.84% -18.64%
Operating Cash Flow Q/Q Growth		 -31.83% 89.06% -868.79% 5.26% -27.09% 56.52% -212.77% 2.15% - -24.14% -7.62%
Free Cash Flow Firm Q/Q Growth		 -85.42% -80.46% -3.49% 11.11% 28.39% -15.63% 13.82% -5.72% - -204.16% -26.90%
Invested Capital Q/Q Growth		 37.30% -33.54% 20.74% 8.20% 54.78% -183.01% -4.04% 17.53% - 100.75% 7,059.06%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBITDA Margin		 -8.05% -202.46% -282.88% -559.27% -65.78% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Margin		 -10.60% -209.21% -291.86% -575.24% -69.16% 0.00% 0.00% 0.00% - 0.00% 0.00%
EBIT Margin		 -10.60% -209.21% -291.86% -575.24% -69.16% 0.00% 0.00% 0.00% - 0.00% 0.00%
Profit (Net Income) Margin		 -6.30% -199.60% -276.97% -555.20% -63.94% 0.00% 0.00% 0.00% - 0.00% 0.00%
Tax Burden Percent		 99.30% 100.00% 100.00% 100.00% 101.61% 100.62% 100.00% 100.00% - 100.00% 100.00%
Interest Burden Percent		 59.90% 95.40% 94.90% 96.52% 90.98% 97.08% 93.53% 93.51% - 92.32% 94.85%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Equity (ROE)		 -129.63% -197.34% -392.69% -102.63% -48.16% -75.39% -120.15% -107.79% - -56.40% -73.70%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - -109,122.26% -1,793.87%
Operating Return on Assets (OROA)		 -4.90% -109.76% -188.04% -205.40% -13.44% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Assets (ROA)		 -2.92% -104.71% -178.44% -198.25% -12.42% 0.00% 0.00% 0.00% - 0.00% 0.00%
Return on Common Equity (ROCE)		 -129.63% -197.34% -392.69% -102.63% -48.16% -75.39% -120.15% -107.79% - -56.40% -73.70%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -131.89% -242.96% -49.97% 0.00% -43.14% 0.00% 0.00% - 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.90 -7.19 -8.11 -9.11 -5.39 -17 -19 -18 -20 -26 -30
NOPAT Margin		 -7.42% -146.45% -204.31% -402.67% -48.41% 0.00% 0.00% 0.00% - 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.35% -6.61% -9.50% -6.46% -1.81% -7.60% -8.74% -6.85% - -3.87% -5.89%
Return On Investment Capital (ROIC_SIMPLE)		 -3.97% - - - -3.70% -13.70% -18.48% -21.94% -6.67% -9.24% -12.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
SG&A Expenses to Revenue		 28.37% 82.98% 77.00% 153.15% 38.39% 0.00% 0.00% 0.00% - 0.00% 0.00%
R&D to Revenue		 82.23% 226.23% 314.87% 522.09% 130.77% 0.00% 0.00% 0.00% - 0.00% 0.00%
Operating Expenses to Revenue		 110.61% 309.21% 391.86% 675.24% 170.17% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.28 -10 -12 -13 -7.70 -25 -28 -26 -29 -37 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.97 -9.93 -11 -13 -7.32 -25 -27 -26 -29 -36 -42
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.66 11.57 13.19 7.25 4.31 3.40 4.32 3.93 - 6.27 5.66
Price to Tangible Book Value (P/TBV)		 6.66 11.57 13.19 7.25 4.31 3.40 4.32 3.93 - 6.27 5.66
Price to Revenue (P/Rev)		 5.98 7.87 5.59 21.31 28.18 24.96 33.89 29.61 - 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 15,851.26 174.24
Enterprise Value to Revenue (EV/Rev)		 4.41 6.52 4.63 17.79 21.37 16.63 24.72 20.76 - 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.18 0.29 0.05 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to Equity		 0.00 0.18 0.29 0.05 0.00 0.00 0.00 0.00 - 0.00 0.00
Financial Leverage		 -2.26 -3.20 -4.27 -1.61 -1.14 -1.24 -1.28 -1.18 - -1.04 -1.03
Leverage Ratio		 3.16 4.19 5.92 1.96 1.36 1.39 1.48 1.44 - 1.18 1.43
Compound Leverage Factor		 1.90 4.00 5.62 1.89 1.24 1.35 1.38 1.35 - 1.09 1.36
Debt to Total Capital		 0.00% 15.48% 22.69% 4.71% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 15.48% 22.69% 4.71% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Common Equity to Total Capital		 100.00% 84.52% 77.31% 95.29% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00%
Debt to EBITDA		 0.00 -0.14 -0.12 -0.10 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to EBITDA		 0.00 1.46 0.91 2.35 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.14 -0.12 -0.10 0.00 0.00 0.00 0.00 - 0.00 0.00
Debt to NOPAT		 0.00 -0.18 -0.16 -0.13 0.00 0.00 0.00 0.00 - 0.00 0.00
Net Debt to NOPAT		 0.00 2.00 1.24 3.23 0.00 0.00 0.00 0.00 - 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.18 -0.16 -0.13 0.00 0.00 0.00 0.00 - 0.00 0.00
Altman Z-Score		 -0.54 -0.44 -3.22 9.76 14.39 8.46 7.18 1.70 - 21.14 5.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.63 1.57 1.37 4.19 7.77 6.55 4.37 3.59 - 8.42 7.35
Quick Ratio		 1.26 1.51 1.32 4.15 7.21 6.48 4.32 3.50 - 8.28 7.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -25 -25 -23 -16 -19 -16 -17 -14 -43 -55
Operating Cash Flow to CapEx		 -2,075.54% -208.42% -20,365.43% -127,309.72% -3,027.08% -718.02% -6,993.24% -35,257.39% - -571.19% -774.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.46 0.52 0.64 0.36 0.19 0.17 0.16 0.10 - 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Fixed Asset Turnover		 4.96 5.06 5.22 4.44 4.00 2.89 1.97 1.36 - 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -17 -18 -15 -13 -6.05 -17 -18 -15 -12 0.09 6.64
Invested Capital Turnover		 -1.16 -1.00 -1.17 -1.15 -1.94 -0.98 -0.83 -0.79 - 0.00 0.00
Increase / (Decrease) in Invested Capital		 9.64 17 17 14 11 1.27 -3.24 -1.31 -6.28 17 24
Enterprise Value (EV)		 111 177 126 413 476 289 331 231 - 1,470 1,157
Market Capitalization		 151 213 152 495 627 433 454 330 - 1,748 1,395
Book Value per Share		 $0.73 $0.59 $0.36 $2.10 $3.20 $2.79 $2.30 $1.83 $6.69 $4.85 $4.25
Tangible Book Value per Share		 $0.73 $0.59 $0.36 $2.10 $3.20 $2.79 $2.30 $1.83 $6.69 $4.85 $4.25
Total Capital		 23 22 15 72 145 128 105 84 306 279 246
Total Debt		 0.00 3.38 3.38 3.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 3.38 3.38 3.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -39 -37 -26 -82 -152 -145 -123 -99 -318 -279 -238
Capital Expenditures (CapEx)		 0.56 0.61 0.06 0.01 0.49 0.90 0.29 0.06 1.66 5.12 4.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -25 -21 -20 -9.16 -21 -27 -26 -31 -29 -29
Debt-free Net Working Capital (DFNWC)		 20 15 8.31 65 142 124 96 73 287 249 209
Net Working Capital (NWC)		 20 15 8.31 65 142 124 96 73 287 249 209
Net Nonoperating Expense (NNE)		 -0.13 2.61 2.89 3.45 1.73 6.90 6.51 6.17 9.76 8.20 11
Net Nonoperating Obligations (NNO)		 -39 -37 -26 -82 -152 -145 -123 -99 -318 -279 -240
Total Depreciation and Amortization (D&A)		 0.31 0.33 0.36 0.36 0.38 0.41 0.49 0.49 0.50 0.53 0.56
Debt-free, Cash-free Net Working Capital to Revenue		 -79.05% -91.85% -77.89% -84.73% -41.12% -120.16% -202.14% -231.46% - 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 77.79% 55.46% 30.62% 281.33% 639.23% 713.64% 714.82% 654.09% - 0.00% 0.00%
Net Working Capital to Revenue		 77.79% 55.46% 30.62% 281.33% 639.23% 713.64% 714.82% 654.09% - 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62) ($0.59) ($0.70)
Adjusted Weighted Average Basic Shares Outstanding		 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M 57.43M 57.93M
Adjusted Diluted Earnings per Share		 $0.02 ($0.31) ($0.35) ($0.38) ($0.11) ($0.53) ($0.57) ($0.54) ($0.62) ($0.59) ($0.70)
Adjusted Weighted Average Diluted Shares Outstanding		 26.78M 31.35M 31.84M 33.09M 35.22M 45.64M 45.71M 45.72M 46.48M 57.43M 57.93M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 31.40M 31.81M 32.54M 45.47M 45.68M 45.71M 45.72M 45.72M 57.51M 57.91M 58.14M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.90 -7.19 -8.11 -9.11 -5.39 -17 -19 -18 -20 -26 -30
Normalized NOPAT Margin		 -7.42% -146.45% -204.31% -402.67% -48.41% 0.00% 0.00% 0.00% - 0.00% 0.00%
Pre Tax Income Margin		 -6.35% -199.60% -276.97% -555.20% -62.92% 0.00% 0.00% 0.00% - 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Capricor Therapeutics (NASDAQ: CAPR) continues to look like a development-stage biotech with a very large cash position, ongoing operating losses, and no commercial revenue in the latest quarter. The company’s balance sheet improved dramatically in recent quarters after a large equity raise and investment activity, giving it a strong liquidity cushion for now.

  • Cash and investments are very strong. As of Q1 2026, Capricor reported $105.4 million in cash and equivalents and $173.2 million in short-term investments, or about $278.6 million of liquid resources.
  • Book equity remains high. Total common equity was $278.7 million in Q1 2026, supported by the company’s cash raised and investment balance.
  • Interest income is helping offset losses. Q1 2026 interest and investment income was $2.9 million, which partially reduced the impact of operating losses.
  • Balance sheet leverage appears low. Total liabilities were only $47.6 million in Q1 2026, far below total assets of $326.3 million.
  • Share count has risen sharply, likely improving funding runway. The company has used equity issuance repeatedly, most recently in late 2025, which helped strengthen liquidity.
  • There is still no revenue in the latest quarter. Q1 2026 revenue was $0, so the company remains dependent on financing and investment income.
  • Operating cash burn remains substantial. Net cash used in operating activities was $29.3 million in Q1 2026, versus $23.6 million in Q4 2025.
  • R&D spending remains the largest cost line. Q1 2026 research and development expense was $27.4 million, showing continued investment in the pipeline.
  • Deferred revenue remains on the books. Current deferred revenue was $12.0 million in Q1 2026, but this is not enough to make the company meaningfully revenue-generating yet.
  • Losses widened in Q1 2026. Net loss was $33.9 million, up from $30.2 million in Q4 2025.
  • Operating losses are persistent and large. Q1 2026 operating loss was $36.8 million, reflecting a heavy cost structure without product sales.
  • Cash usage accelerated in recent quarters. Net change in cash and equivalents was a negative $182.4 million in Q1 2026, driven largely by investment activity and operating losses.
  • Historical results show a repeated need for capital raises. Over the last several years, Capricor has frequently relied on common equity issuance to fund operations.

Big-picture trend: Capricor’s financial profile has improved on the liquidity side, but not yet on the business model side. The company now has a sizeable cash cushion, which reduces near-term financing risk, but it is still burning cash at a meaningful rate and has not yet generated sustained revenue. For retail investors, the main takeaway is that CAPR looks funded for the time being, but the investment case still hinges on clinical progress and eventual commercialization rather than current fundamentals.

08/16/26 02:45 AM ETAI Generated. May Contain Errors.

Capricor Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Capricor Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Capricor Therapeutics' net income appears to be on an upward trend, with a most recent value of -$105.04 million in 2025, rising from -$12.86 million in 2015. The previous period was -$40.47 million in 2024. Check out Capricor Therapeutics' forecast to explore projected trends and price targets.

Capricor Therapeutics' total operating income in 2025 was -$108.14 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $108.30 million

Over the last 10 years, Capricor Therapeutics' total revenue changed from $5.52 million in 2015 to $0.00 in 2025, a change of -100.0%.

Capricor Therapeutics' total liabilities were at $50.16 million at the end of 2025, a 100.5% increase from 2024, and a 193.3% increase since 2015.

In the past 10 years, Capricor Therapeutics' cash and equivalents has ranged from $3.20 million in 2016 to $287.85 million in 2025, and is currently $287.85 million as of their latest financial filing in 2025.

Over the last 10 years, Capricor Therapeutics' book value per share changed from -0.06 in 2015 to 6.69 in 2025, a change of -10,633.2%.


Related Companies

Financial statements for NASDAQ:CAPR last updated on 8/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
The Greatest Wealth Transfer Since the Internet Boom Just Started
Wall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...
Altimetry | Sponsoredtc pixel
"Second Wave” Hitting Iran Soon? Wall Street Issues Warning
Analysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas ...
TradeSmith | Sponsoredtc pixel
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...
Brownstone Research | Sponsoredtc pixel